Shlomit Schaal to Bevacizumab
This is a "connection" page, showing publications Shlomit Schaal has written about Bevacizumab.
Connection Strength
2.170
-
Schaal S, Sherman MP, Nesmith B, Barak Y. UNTREATED OBSTRUCTIVE SLEEP APNEA HINDERS RESPONSE TO BEVACIZUMAB IN AGE-RELATED MACULAR DEGENERATION. Retina. 2016 Apr; 36(4):791-7.
Score: 0.507
-
Ozkok A, Schaal S. Reply: To PMID 25748280. Retina. 2015 Sep; 35(9):e56-7.
Score: 0.487
-
Ozkok A, Saleh OA, Sigford DK, Heroman JW, Schaal S. THE OMAR STUDY: Comparison of Ozurdex and Triamcinolone Acetonide for Refractory Cystoid Macular Edema in Retinal Vein Occlusion. Retina. 2015 Jul; 35(7):1393-400.
Score: 0.481
-
Rifkin L, Schaal S. Shortening ocular pain duration following intravitreal injections. Eur J Ophthalmol. 2012 Nov-Dec; 22(6):1008-12.
Score: 0.386
-
Jusufbegovic D, Mugavin MO, Schaal S. EVOLUTION OF CONTROLLING DIABETIC RETINOPATHY: Changing Trends in the Management of Diabetic Macular Edema at a Single Institution Over the Past Decade. Retina. 2015 May; 35(5):929-34.
Score: 0.119
-
Nesmith BL, Ihnen M, Schaal S. Poor responders to bevacizumab pharmacotherapy in age-related macular degeneration and in diabetic macular edema demonstrate increased risk for obstructive sleep apnea. Retina. 2014 Dec; 34(12):2423-30.
Score: 0.115
-
Schaal S, Kaplan HJ, Tezel TH. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? Ophthalmology. 2008 Dec; 115(12):2199-205.
Score: 0.076